Glenmark Pharmaceuticals Ltd Q4 FY26 Earnings Analysis

- TEVIMBRA and BRUKINSA showing strong sales with massive current run rate (Page 17). - FY '28 expected to exceed $50 million collectively from new assets excluding RYALTRIS (Page 17). - India market growing strong at 19% vs market growth of 10-11%; expected to remain strong for 3-5 years with oncology and chronic respiratory driving growth (Page 17). - Europe business anticipated to grow at high single to low double digits in coming years, aided by new respiratory product launches like RYALTRIS and WINLEVI (Page 10). - Next 5 years’ growth driven by 7-8 innovative assets including Aumolertinib, Hengrui assets, RYALTRIS, WINLEVI, TEVIMBRA, BRUKINSA (Page 9). - U.S. expected to have a strong finish in FY '26 with new respiratory launches anticipated in Q4; Monroe plant to contribute with new product approvals (Pages 7, 9). - Overall, strong growth outlook with expansion into innovative branded assets and emerging markets (Pages 7, 17).

- FY '28 is expected to see significant growth driven by launches of innovative assets including Aumolertinib and Hengrui products. - EBITDA margins expected to expand beyond current guidance due to increasing branded mix, emerging market strength, and operating leverage from fixed cost base. - India business projected to sustain strong growth with a 19% growth in December vs. 10-11% market growth, supported by chronic respiratory and oncology launches. - Europe to grow at high single to low double digit in constant currency, supported by upcoming respiratory product launches and RYALTRIS sales. - Specialty and innovative portfolio (e.g., oncology assets like TEVIMBRA, BRUKINSA) expected to have higher gross and EBITDA margins, contributing to margin uplift from FY '28 onwards. - Capex maintained at INR800 crores annually to support commercial and R&D expansions, aiding growth trajectory. - Ichnos-related revenues stable at $70 million annualized. - Overall, Glenmark aims to continue strong earnings growth and margin improvement while moving up the value chain with next 5-10 year innovation focus.

- Planned capex for the next fiscal year is around INR 700-800 crores annually. - Investments primarily go into: - Ongoing capex on plants and expanding current manufacturing lines and facilities. - Strategic in-licensing products such as the Hengrui asset. - No current in-house biologic manufacturing; biologics manufacturing is outsourced, but future developments unknown. - Capex mix: approximately 55% intangible assets (e.g., licensing, product acquisition) and 45% tangible assets (e.g., plant expansion). - Capex for the recent quarter was around INR 215 crores, with year-to-date capex at INR 715 crores. - The company is focused on complex injectable products and expanding filing activity at manufacturing sites for growth. - No specific disclosures on additional partnering timelines or deal scopes for current assets related to capex investments.

- There is no specific mention or visibility provided on any upcoming new fundraising through debt or equity in the provided document pages. - The company remains net cash positive with around INR600 crores net cash and gross debt close to INR600 crores as of December 31, 2025. - Capex for the next fiscal year is planned around INR700-800 crores, mostly for plant expansions and in-licensing products, but no mention of raising new funds for these. - Management emphasizes managing working capital efficiently and maintaining financial health but does not indicate plans for additional debt or equity fundraising. - Partnership discussions focus more on optimal timing rather than immediate capital raising through public or private markets.

The transcripts from Glenmark Pharmaceuticals Limited's Q3 FY '26 Earnings Conference Call do not explicitly mention current or expected orderbook or pending orders. However, some related operational insights include: - Glenmark expects at least 3 complex injectable filings annually from the Monroe site, with commercial production starting this quarter (Page 9). - Specialty products like RYALTRIS are growing significantly, with expectations to reach $200-250 million over 3-5 years (Page 16). - New innovative assets like Aumolertinib and Hengrui portfolio are projected to drive meaningful revenue growth from FY '28, exceeding $50 million excluding RYALTRIS (Page 17). - The company is prepared for product launches tied to licensing deals, with milestone payments expected in Q4 or early next quarter (Page 12). No specific numbers or direct commentary on orderbook or pending orders were disclosed.